Maiva Pharma has inaugurated a new sterile injectables manufacturing facility in Shoolagiri, Tamil Nadu, India, expanding its CDMO capabilities for generic and complex injectable products. The 22-acre site, equipped with high-speed vial filling, pre-filled syringe, cartridge, and lyophilization lines, positions the company as a stronger partner for pharmaceutical and biotechnology firms seeking reliable sterile injectable supply chains.
Facility expansion details
The newly commissioned facility is built on a 22-acre site and will eventually house six manufacturing lines. Phase I includes three dedicated production lines: a high-speed vial filling line, an integrated pre-filled syringe and cartridge line, and a lyophilization line. The site also features advanced Quality Control chemical laboratories and state-of-the-art microbiology labs for in-house analytical testing and quality assurance.
Product portfolio and capabilities
Maiva Pharma focuses on sterile injectables as a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO). The facility can produce a wide range of dosage forms, including vials, pre-filled syringes (PFS), cartridges, suspension products, and lyophilized formulations. This diversification supports global pharmaceutical and biotechnology partners in meeting evolving market requirements.
Strategic significance for global buyers
Dr. Bhaskar Krishna, Managing Director and CEO of Maiva Pharma, stated, "The inauguration of our Shoolagiri facility represents a major step in Maiva Pharma’s journey to become a globally preferred partner in sterile injectables manufacturing." He added, "With advanced manufacturing technologies, expanded capacity, and diversified delivery system capabilities, we are well-positioned to support our customers’ evolving needs and accelerate access to high-quality injectable therapies worldwide."
Sourcing context
For overseas importers, distributors, and clinic buyers of sterile injectables, Maiva Pharma's expanded capacity offers a reliable supply option for generic and complex formulations. The facility's flexible production infrastructure and robust quality systems align with global regulatory standards, making it a viable partner for those seeking to diversify their injectable product sourcing in the medical aesthetics and pharmaceutical sectors.
Source: Read the original report | Published: June 19, 2026